Deutsches Krebsforschungszentrum; Stiftung des öffentlichen Rechts
发明人:
申请号:
EP18182128.1
公开号:
EP3590935A1
申请日:
2018.07.06
申请国别(地区):
EP
年份:
2020
代理人:
摘要:
The present invention pertains to fused imidazolium derivatives, in particular 11-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-naphtho(2,3-d)imidazolium bromide for use in the treatment of colorectal cancer (CRC). The invention provides the therapeutic application of such compounds in a patient subgroup of CRC, which is characterized by a consensus molecular subtype (CMS) 1.